We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00895622
Previous Study | Return to List | Next Study

Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00895622
First Posted: May 8, 2009
Last Update Posted: October 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Cancer Institute (NCI)
NRG Oncology
Information provided by (Responsible Party):
Radiation Therapy Oncology Group
  Purpose

RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy, may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether observation is more effective than radiation therapy in treating patients with meningioma.

PURPOSE: This phase II trial is studying observation to see how well it works compared with radiation therapy in treating patients with grade I, grade II, or grade III meningioma.


Condition Intervention Phase
Brain and Central Nervous System Tumors Other: clinical observation Radiation: 3-dimensional conformal radiation therapy Radiation: intensity-modulated radiation therapy (IMRT) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas

Resource links provided by NLM:


Further study details as provided by Radiation Therapy Oncology Group:

Primary Outcome Measures:
  • Progression-free survival rate at 3 years [ Time Frame: From registration to 3 years ]

Secondary Outcome Measures:
  • Grades 2-5 neurology, ocular/visual, dermatologic/skin [excluding alopecia] categories, individually and combined for acute adverse events as assessed by NCI CTCAE v3.0 [ Time Frame: From start of radiation to 90 days ]
    Grades 2-5 neurology, ocular/visual, dermatologic/skin [excluding alopecia] categories, individually and combined for acute adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 where the attribution is related to treatment as definite, probable, possible, or unknown.

  • Grades 2-5 neurology, ocular/visual, dermatologic/skin [excluding alopecia] categories, individually and combined for late adverse events as assessed by NCI CTCAE v3.0 [ Time Frame: From 91 days after start of radiation to death or 10 years, whichever is first ]
    Grades 2-5 neurology, ocular/visual, dermatologic/skin [excluding alopecia] categories, individually and combined for late adverse events as assessed by NCI CTCAE v3.0 where the attribution is related to treatment as definite, probable, possible, or unknown.

  • Survival rate at 3 years [ Time Frame: From registration to 3 years ]
  • MRI imaging predictors as assessed by central neuroradiology review at diagnosis, at any failure, and at 3 years [ Time Frame: From registration to 3 years ]
  • Adherence to protocol-specific target and normal tissue radiotherapy parameters [ Time Frame: After treatment delivery ]
  • Concordance between central and parent institution histopathologic grading and subtyping [ Time Frame: From 4 weeks of block receipt for central review of eligibility. ]

Enrollment: 244
Study Start Date: June 2009
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Group 1
Patients undergo clinical observation.
Other: clinical observation
Patients undergo observation.
Experimental: Group 2
Patients undergo 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks.
Radiation: 3-dimensional conformal radiation therapy
Patients undergo 3-dimensional conformal radiation therapy once daily 5 days a week for 6 weeks
Radiation: intensity-modulated radiation therapy (IMRT)
Patients undergo IMRT once daily 5 days a week for 6 weeks
Experimental: Group 3
Patients undergo IMRT once daily 5 days a week for 6 weeks.
Radiation: intensity-modulated radiation therapy (IMRT)
Patients undergo IMRT once daily 5 days a week for 6 weeks

Detailed Description:

OBJECTIVES:

Primary

  • To estimate the rates of progression-free survival at 3 years in patients with low-risk meningioma undergoing observation and in patients with intermediate- or high-risk meningioma undergoing radiotherapy.

Secondary

  • To study the concordance, or lack thereof, between central and parent institution histopathologic diagnosis, grading, and subtyping.
  • To estimate the rates of overall survival at 3 years in these patients.
  • To estimate the incidence rates of acute and late adverse events ≥ grade 2 in patients with intermediate- or high-risk meningioma undergoing radiotherapy.
  • To evaluate MRI imaging predictors by central neuroradiology review at diagnosis, at any failure, and at 3 years.
  • To evaluate adherence to protocol-specific target and normal tissue radiotherapy parameters.

OUTLINE: This is a multicenter study. Patients are assigned to 1 of 3 groups according to risk.

  • Group 1 (low-risk disease): Patients undergo observation.
  • Group 2 (intermediate-risk disease): Patients undergo 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks.
  • Group 3 (high-risk disease): Patients undergo IMRT once daily 5 days a week for 6 weeks.

After completion of study treatment, patients are followed up every 3-6 months for 3 years and then annually for 10 years.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed meningioma, meeting 1 of the following criteria:

    • Low-risk disease, as defined by the following:

      • Newly diagnosed, WHO grade I disease that was gross totally resected (Simpson's grade I, II, or III resection with no residual nodular enhancement on postoperative imaging) or subtotally resected (residual nodular enhancement or Simpson grade IV or V resection)
    • Intermediate-risk disease, as defined by the following:

      • Newly diagnosed, WHO grade II disease that was gross totally resected OR recurrent WHO grade I disease irrespective of the resection extent
    • High-risk disease, as defined by 1 of the following:

      • Newly diagnosed or recurrent WHO grade III disease of any resection extent
      • Recurrent WHO grade II disease of any resection extent
      • Newly diagnosed, WHO grade II disease that was subtotally resected
  • Patients with newly diagnosed disease must have had a histologic diagnosis within the past 6 months AND have undergone pre- and post-operative MRIs within the past 3 months
  • Patients with recurrent/progressive intermediate- or high-risk disease who have not undergone recent surgery must have documentation of recurrence or progression by MRI within the past 3 months
  • No extracranial or multiple meningioma and/or hemangiopericytoma

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-1
  • Negative pregnancy test (for patients enrolled in groups 2 or 3)
  • Fertile patients must use effective contraception (for patients enrolled in groups 2 or 3)
  • Able to receive gadolinium
  • No other invasive malignancy within the past 3 years except for nonmelanoma skin cancer or carcinoma in situ of the breast, oral cavity, or cervix
  • No severe, active comorbidity including, but not limited to, any of the following:

    • Unstable angina and/or congestive heart failure requiring hospitalization
    • Transmural myocardial infarction within the past 6 months
    • Acute bacterial and/or fungal infection requiring IV antibiotics
    • Chronic obstructive pulmonary disease exacerbation or respiratory illness requiring hospitalization or that would preclude study treatment
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    • Known HIV positivity or AIDS, based upon the current Centers for Disease Control (CDC) definition
    • No evidence of active connective tissue disorders (e.g., lupus erythematosus and/or scleroderma) (for patients enrolled in groups 2 or 3)
  • No other major medical illness or psychiatric impairment that, in the investigator's opinion, would preclude study treatment or informed consent

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior radiotherapy to the scalp, cranium, brain, or skull base
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00895622


  Show 78 Study Locations
Sponsors and Collaborators
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
NRG Oncology
Investigators
Principal Investigator: C. Leland Rogers, MD Virginia Commonwealth University
  More Information

Responsible Party: Radiation Therapy Oncology Group
ClinicalTrials.gov Identifier: NCT00895622     History of Changes
Other Study ID Numbers: RTOG-0539
CDR0000641815
First Submitted: May 7, 2009
First Posted: May 8, 2009
Last Update Posted: October 12, 2016
Last Verified: October 2016

Keywords provided by Radiation Therapy Oncology Group:
adult grade I meningioma
adult grade II meningioma
adult grade III meningioma
adult anaplastic meningioma
adult papillary meningioma
recurrent adult brain tumor

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Meningioma
Neoplasms by Site
Neoplasms
Nervous System Diseases
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Meningeal Neoplasms